JP2017516458A - ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関 - Google Patents

ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関 Download PDF

Info

Publication number
JP2017516458A
JP2017516458A JP2016558594A JP2016558594A JP2017516458A JP 2017516458 A JP2017516458 A JP 2017516458A JP 2016558594 A JP2016558594 A JP 2016558594A JP 2016558594 A JP2016558594 A JP 2016558594A JP 2017516458 A JP2017516458 A JP 2017516458A
Authority
JP
Japan
Prior art keywords
hgf
patient
antibody
biomarker
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016558594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516458A5 (enExample
Inventor
ウェイ ユイ，
ウェイ ユイ，
デーヴィッド シェイムズ，
デーヴィッド シェイムズ，
ハルトムート ケッペン，
ハルトムート ケッペン，
シー ファン，
シー ファン，
サンドラ ロスト，
サンドラ ロスト，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2017516458A publication Critical patent/JP2017516458A/ja
Publication of JP2017516458A5 publication Critical patent/JP2017516458A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0241—Advertisements
    • G06Q30/0251—Targeted advertisements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00—Nucleic acid detection characterised by assay method
    • C12Q2561/113—Real time assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Business, Economics & Management (AREA)
  • Strategic Management (AREA)
  • Finance (AREA)
  • Development Economics (AREA)
  • Accounting & Taxation (AREA)
  • Mycology (AREA)
  • Economics (AREA)
  • Marketing (AREA)
JP2016558594A 2014-03-24 2015-03-24 ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関 Pending JP2017516458A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461969706P 2014-03-24 2014-03-24
US61/969,706 2014-03-24
US201461985316P 2014-04-28 2014-04-28
US61/985,316 2014-04-28
PCT/US2015/022282 WO2015148531A1 (en) 2014-03-24 2015-03-24 Cancer treatment with c-met antagonists and correlation of the latter with hgf expression

Publications (2)

Publication Number Publication Date
JP2017516458A true JP2017516458A (ja) 2017-06-22
JP2017516458A5 JP2017516458A5 (enExample) 2018-05-17

Family

ID=52829364

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016558594A Pending JP2017516458A (ja) 2014-03-24 2015-03-24 ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関

Country Status (11)

Country Link
US (1) US10240207B2 (enExample)
EP (1) EP3122900A1 (enExample)
JP (1) JP2017516458A (enExample)
KR (1) KR20160137599A (enExample)
CN (1) CN107002119A (enExample)
BR (1) BR112016021383A2 (enExample)
CA (1) CA2943329A1 (enExample)
MA (1) MA39776A (enExample)
MX (1) MX2016012285A (enExample)
RU (1) RU2016141385A (enExample)
WO (1) WO2015148531A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10281374B2 (en) * 2015-11-04 2019-05-07 Diagnostic Biosystems Method of pretreatment of biological samples for an analyte-staining assay method
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN105734159B (zh) * 2016-04-29 2019-04-05 北京泱深生物信息技术有限公司 食管鳞癌的分子标记物
KR102476709B1 (ko) 2016-11-21 2022-12-09 나노스트링 테크놀로지스, 인크. 화학적 조성물 및 이것을 사용하는 방법
US10379015B2 (en) 2017-06-04 2019-08-13 Diagnostic Biosystems Method for labeling concentration density differentials of an analyte in a biological sample
CN119798437A (zh) * 2017-08-08 2025-04-11 豪夫迈·罗氏有限公司 一种dlbcl患者亚组的奥滨尤妥珠单抗治疗
CN109422815A (zh) * 2017-08-28 2019-03-05 复旦大学 双特异性嵌合抗原受体c-Met/PD-1 scFv-CAR-T及其构建方法和应用
CA3091373A1 (en) * 2018-02-17 2019-08-22 Apollomics Inc. Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
JP7525402B2 (ja) 2018-05-14 2024-07-30 ナノストリング テクノロジーズ，インコーポレイティド 化学的組成物とそれを利用する方法
CN109666748A (zh) * 2019-02-01 2019-04-23 常州诺赛生物科技有限公司 脐带间充质干细胞在治疗肝病方面生物学效力的评价方法
US20200341002A1 (en) * 2019-04-17 2020-10-29 Cleveland State University Methods for quantitating protein biomarkers
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
US11866493B2 (en) * 2019-11-01 2024-01-09 East Tennessee State University Research Foundation Single-chain variable fragment of Met monoclonal antibody and methods of use in CAR T cell therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045344A1 (en) * 2008-10-17 2010-04-22 Genentech, Inc. Combination therapy comprising a c-met antagonist and a vegf antagonist
JP2012072140A (ja) * 2010-09-29 2012-04-12 Pfizer Inc 異常な細胞増殖を処置する方法
WO2013043715A1 (en) * 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists
JP2013537966A (ja) * 2010-08-31 2013-10-07 ジェネンテック， インコーポレイテッド バイオマーカー及び治療の方法

Family Cites Families (294)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8318575D0 (en) 1983-07-08 1983-08-10 Cobbold S P Antibody preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
CA1340530C (en) 1989-04-28 1999-05-04 Kok Kheong Lee Synthetic pseudomonas aeruginosa pilin peptide and related vaccines and diagnostics
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
CA2066428C (en) 1989-09-08 2000-11-28 Bert Vogelstein Structural alterations of the egf receptor gene in human gliomas
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5362716A (en) 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
US5648273A (en) 1989-12-27 1997-07-15 The United States Of America, As Represented By The Department Of Health And Human Services Hepatic growth factor receptor is the MET proto-oncogene
US5871959A (en) 1989-12-27 1999-02-16 The United States Of America As Represented By The Department Of Health And Human Services Method of producing hepatocycte growth factor/scatter factor and related cell lines
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE256736T1 (de) 1990-09-14 2004-01-15 Us Health Ein nicht-mitogener kompetitiver hgf-antagonist
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
ATE155525T1 (de) 1991-05-10 1997-08-15 Pharmacia & Upjohn Spa Verkürzte formen den hepatozyten wachstumsfaktor (hgf) rezeptors
US5227158A (en) 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
SE9103649D0 (sv) 1991-12-10 1991-12-10 Aga Ab Fyllning av luftkudde
AU3416693A (en) 1991-12-18 1993-07-19 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University, The Antigenic preparations that stimulate production of antibodies which bind to the pili of type IV piliated bacteria
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5328837A (en) 1992-05-18 1994-07-12 Genentech, Inc. Hepatocyte growth factor protease domain variants
ES2257734T3 (es) 1992-05-18 2006-08-01 Genentech, Inc. Activacion de los receptores de oligomerizacion por medio de los ligandos de receptores fusionados.
WO1993023541A1 (en) 1992-05-18 1993-11-25 Genentech, Inc. Hepatocyte growth factor variants
US5316921A (en) 1992-05-18 1994-05-31 Genentech, Inc. Single-chain hepatocyte growth factor variants
AU675440B2 (en) 1992-06-18 1997-02-06 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant (pseudomonas) exotoxin with increased activity
CA2144856A1 (en) 1992-09-18 1994-03-31 Donna L. Faletto A method of preventing tumor metastasis
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5550362A (en) 1992-11-20 1996-08-27 Intermec Corporation Method and apparatus for calibrating a bar code scanner
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
CA2142713A1 (en) 1993-06-30 1995-01-12 Paolo Comoglio Peptide inhibitors of mitogenesis and motogenesis
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5869049A (en) 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
DK0659439T3 (da) 1993-12-24 2002-01-14 Merck Patent Gmbh Immunkonjugater
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5747662A (en) 1995-03-01 1998-05-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6242177B1 (en) 1995-03-01 2001-06-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
EP0836605B1 (en) 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP2000515735A (ja) 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
AU4155697A (en) 1996-08-23 1998-03-06 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
IL132240A0 (en) 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
DE69832970T2 (de) 1997-04-07 2006-08-10 Genentech, Inc., South San Francisco Humanisierte antikörper und verfahren zu ihrer herstellung
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2201484T3 (es) 1997-05-06 2004-03-16 Wyeth Holdings Corporation Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal.
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
NZ503991A (en) 1997-11-06 2001-11-30 American Cyanamid Co Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
CA2328495A1 (en) 1998-05-06 1999-11-11 The Governors Of The University Of Alberta Vaccine for pseudomonas aeruginosa
WO1999060023A1 (en) 1998-05-15 1999-11-25 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
ES2188254T3 (es) 1998-11-19 2003-06-16 Warner Lambert Co N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas.
DE19858253A1 (de) 1998-12-17 2000-06-21 Aventis Pharma Gmbh Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
EP2042194A3 (en) 1999-05-14 2009-04-22 Imclone Systems, Inc. Treatment of refractory human tumors with epidermal growth factor receptor antagonists
DE60042021D1 (de) 1999-07-29 2009-05-28 Gilead Sciences Inc Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
CN100376567C (zh) 1999-11-05 2008-03-26 阿斯特拉曾尼卡有限公司 作为vegf抑制剂的喹唑啉衍生物
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
ES2274823T3 (es) 1999-12-29 2007-06-01 Immunogen, Inc. Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
AU9500201A (en) 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
AU2002245142B2 (en) 2000-12-14 2007-07-05 Genentech, Inc. Prokaryotically produced antibodies and uses thereof
WO2002096361A2 (en) 2001-05-30 2002-12-05 Sugen, Inc. 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
CA2454538A1 (en) 2001-06-22 2003-01-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
CN100513414C (zh) 2001-08-27 2009-07-15 杰南技术公司 进行抗体表达和装配的系统
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
EP1463507A1 (en) 2001-12-19 2004-10-06 SmithKline Beecham Corporation Thienopyrimidine compounds as protein tyrosine kinase inhibitors
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7332580B2 (en) 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
HRP20050986A2 (en) 2002-08-19 2006-11-30 Abgenix Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
AU2003272740A1 (en) 2002-10-01 2004-04-23 Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1578447A4 (en) 2002-10-31 2009-06-03 Genentech Inc METHOD AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
EP1592713A2 (en) 2003-02-13 2005-11-09 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
RS53118B (sr) 2003-02-26 2014-06-30 Sugen Inc. Aminoheteroaril jedinjenja kao inhibitori protein kinaze
WO2004087207A2 (en) 2003-03-27 2004-10-14 Georgetown University Method for inducing apoptosis and aneuploidy regression in cancer cells
WO2004092154A1 (en) 2003-04-03 2004-10-28 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
NZ621449A (en) 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
EP2093570A1 (en) 2003-06-06 2009-08-26 Genentech, Inc. Modulating the interaction between HGF beta chain and c-met
US7037909B2 (en) 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
EP1644362A2 (en) 2003-07-02 2006-04-12 Sugen, Inc. Indolinone hydrazides as c-met inhibitors
NZ544797A (en) 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
WO2005016920A1 (en) 2003-08-15 2005-02-24 Vertex Pharmaceuticals Incorporated Pyrrole compositions useful as inhibitors of c-met
EP1697352B1 (en) 2003-09-24 2012-06-27 Vertex Pharmceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
WO2005058965A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
AU2004309347B2 (en) 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
CA2553433A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
JP4932495B2 (ja) 2004-01-23 2012-05-16 アムゲン インコーポレイテッド 化合物及び使用方法
CA2553785C (en) 2004-02-14 2011-02-08 Irm Llc Compounds and compositions as protein kinase inhibitors
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
AU2005249396B2 (en) 2004-05-05 2011-10-20 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
AU2005245386B2 (en) 2004-05-07 2008-11-27 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
EP3042964A1 (en) 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
WO2005121125A1 (en) 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
WO2006014325A2 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
AU2005264685B2 (en) 2004-07-21 2008-02-28 Lg Chem. Ltd. Gas-barrier nanocomposite composition and article using the same
PT1773885E (pt) 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
ATE492544T1 (de) 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
WO2006021886A1 (en) 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
JP2008531557A (ja) 2005-02-23 2008-08-14 メリマック ファーマシューティカルズ インコーポレーティッド 生物活性を調節するための二重特異性結合剤
JP2008538204A (ja) 2005-03-10 2008-10-16 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 安定化側鎖を含む放射性標識複合体キレート剤
US8383357B2 (en) 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
ATE477495T1 (de) 2005-03-16 2010-08-15 Osi Pharm Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
CN101184506B (zh) 2005-03-25 2013-07-17 健泰科生物技术公司 用于调节超稳定化的c-met的方法和组合物
MX2007011650A (es) 2005-03-25 2008-01-16 Genentech Inc Mutaciones de la c-met en el cancer del pulmon.
WO2006108048A1 (en) 2005-04-05 2006-10-12 The General Hospital Corporation Method for predicting responsiveness to drugs
ZA200710599B (en) 2005-04-15 2009-08-26 Genentech Inc HGF Beta chain variants
MX2008000345A (es) 2005-07-08 2008-04-02 Univ Zuerich Visualizacion en fagos usando transcolocacion contraduccional de polipeptidos de fusion.
WO2007042289A2 (en) 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
US7964365B2 (en) 2005-11-08 2011-06-21 The United States of Americam as represented by the Secretary, Department of Health and Human Services Methods for diagnosing and monitoring the progression of cancer
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
KR101146852B1 (ko) 2005-12-05 2012-05-16 화이자 프로덕츠 인크. Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체
AR059246A1 (es) 2006-01-30 2008-03-19 Array Biopharma Inc Compuestos heterobiciclicos de tiofeno y metodos de uso
MX2008011220A (es) 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.
WO2007106503A2 (en) 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
WO2007126788A2 (en) 2006-03-27 2007-11-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the treatment and prevention of viral infection
CL2007000851A1 (es) 2006-03-30 2008-03-14 Novartis Ag Anticuerpo anti receptor del factor de crecimiento del hepatocito (c-met); adn que codifican cadenas livianas y pesadas del anticuerpo; composicion farmaceutica y kit que comprenden dicho anticuerpo; metodo para tratar trastorno relacionado con c-met
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
SG158112A1 (en) 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
JP4560582B2 (ja) 2006-06-02 2010-10-13 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
US20110053931A1 (en) 2006-06-08 2011-03-03 John Gaudino Quinoline compounds and methods of use
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP2043675A2 (en) 2006-07-07 2009-04-08 Washington State University Research Foundation C-met receptor regulation by angiotensin iv (at4) receptor ligands
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
EP2091975A4 (en) 2006-11-21 2013-05-22 Univ California ANTIBODIES TO THE EGFR FAMILY, BICE-SPECIFIC ANTIBODIES TO THE EGFR FAMILY AND METHOD FOR THEIR USE
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US20100062441A1 (en) 2007-03-15 2010-03-11 Ravi Salgia C-met mutations and uses thereof
US20100255004A1 (en) 2007-04-13 2010-10-07 Dana Farber Cancer Institute Receptor tyrosine kinase profiling
ES2529790T3 (es) 2007-04-13 2015-02-25 Dana-Farber Cancer Institute, Inc. Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
US20090042906A1 (en) 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
BRPI0813583A2 (pt) 2007-07-13 2014-12-30 Prometheus Lab Inc Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo
US7892770B2 (en) 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
CN101918403A (zh) 2007-09-06 2010-12-15 阵列生物制药公司 作为酪氨酸激酶抑制剂的吡唑并吡啶类化合物
JP2011522212A (ja) 2007-10-19 2011-07-28 セル・シグナリング・テクノロジー・インコーポレイテツド 癌の分類および使用法
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
GB0803477D0 (en) 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
US20090226455A1 (en) 2008-03-06 2009-09-10 Genentech, Inc. Combination therapy with c-met and her antagonists
MX2010009669A (es) 2008-03-06 2010-09-22 Genentech Inc Terapia de combinacion con antagonistas de c-met y egfr.
TW201002346A (en) 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
CA2734172A1 (en) * 2008-08-29 2010-03-04 Genentech, Inc. Diagnostics and treatments for vegf-independent tumors
US20110229469A1 (en) 2008-10-01 2011-09-22 Ludwig Institute For Cancer Research Methods for the treatment of cancer
BRPI0915240A2 (pt) 2008-10-17 2016-02-16 Genentech Inc método para tratar câncer, método para avaliação de um paciente submetido ao tratamento de câncer, método para avaliação de um paciente que tem ou com suspeita de ter câncer e uso de um anticorpo anti-c-met
CA2741087A1 (en) * 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
EP2342355A4 (en) 2008-10-29 2012-06-27 Beaumont Hospital William PROCESS FOR USE OF BIOMARKERS
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
WO2010093789A2 (en) 2009-02-12 2010-08-19 Arqule, Inc. Combinational compositions and methods for treatment of cancer
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
JP5587975B2 (ja) 2009-04-07 2014-09-10 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体
AU2010233993A1 (en) 2009-04-07 2011-09-08 Roche Glycart Ag Bispecific anti-ErbB-1/anti-c-Met antibodies
AU2010273319B2 (en) * 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
CN101988098A (zh) * 2009-08-07 2011-03-23 芮屈生物技术（上海）有限公司 一种hgf基因的原位杂交检测试剂盒及其检测方法和应用
EP2287197A1 (en) 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
SI2496601T1 (sl) 2009-11-05 2017-09-29 F. Hoffmann-La Roche Ag Tehnike in sestavek za sekrecijo heterolognih polipeptidov
KR101748707B1 (ko) 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
EP2569014A4 (en) 2010-05-14 2013-11-20 Hoffmann La Roche Methods of Treatment
EP2402370A1 (en) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Novel antibody for the diagnosis and/or prognosis of cancer
US8580764B2 (en) 2010-07-01 2013-11-12 Arqule, Inc. Combinational compositions and methods for treatment of cancer
TW201221126A (en) 2010-09-01 2012-06-01 Arqule Inc Methods for treatment of non-small cell lung cancer
WO2013003680A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
US20140234328A1 (en) * 2011-09-09 2014-08-21 Amgen Inc. Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients
MX2014005885A (es) 2011-11-21 2014-09-04 Genentech Inc Purificacion de anticuerpos anti-c-met.
KR101938699B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도
KR101938698B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
US20140030259A1 (en) 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
US20150276748A1 (en) 2012-10-25 2015-10-01 Cedars-Sinai Medical Center Methods of prognosticating and treating cancer
KR20140093347A (ko) 2013-01-15 2014-07-28 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 처리에 의해 부작용을 유발하는 유전자 및 이를 이용한 약물 스크리닝 방법
US20160327559A1 (en) 2014-04-24 2016-11-10 Fundació Institut Mar D'investigacions Mèdiques (Imim) Hepatocyte growth factor as marker of prognosis in small cell lung cancer (sclc)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045344A1 (en) * 2008-10-17 2010-04-22 Genentech, Inc. Combination therapy comprising a c-met antagonist and a vegf antagonist
JP2013537966A (ja) * 2010-08-31 2013-10-07 ジェネンテック， インコーポレイテッド バイオマーカー及び治療の方法
JP2012072140A (ja) * 2010-09-29 2012-04-12 Pfizer Inc 異常な細胞増殖を処置する方法
WO2013043715A1 (en) * 2011-09-19 2013-03-28 Genentech, Inc. Combination treatments comprising c-met antagonists and b-raf antagonists

Also Published As

Publication number Publication date
CN107002119A (zh) 2017-08-01
MA39776A (fr) 2017-02-01
BR112016021383A2 (pt) 2017-10-03
EP3122900A1 (en) 2017-02-01
KR20160137599A (ko) 2016-11-30
MX2016012285A (es) 2017-01-23
US10240207B2 (en) 2019-03-26
US20170183740A1 (en) 2017-06-29
RU2016141385A3 (enExample) 2019-04-03
WO2015148531A1 (en) 2015-10-01
RU2016141385A (ru) 2018-04-28
CA2943329A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
US10240207B2 (en) Cancer treatment with c-met antagonists and correlation of the latter with HGF expression
EP2612151B1 (en) Biomarkers and methods of treatment
JP6845840B2 (ja) Ｐｄ−１及びｐｄ−ｌ１に関連する状態を治療するためのバイオマーカー及び方法
US20150125452A1 (en) Combination treatments comprising c-met antagonists and b-raf antagonists
RS61152B1 (sr) Terapeutski i dijagnostički postupci za lečenje raka
KR20240006698A (ko) 암에 대한 치료 및 진단 방법
JP5606537B2 (ja) 癌患者における診断使用のための方法及び組成物
JP2022512744A (ja) 肉腫様腎臓がんのための診断および治療方法
HK1241936A1 (en) Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
RU2820869C1 (ru) Биомаркеры и способы лечения связанных с pd-1 и pd-l1 состояний
HK1187676A (en) Biomarkers and methods of treatment
AU2016200630A1 (en) Biomarkers and methods of treatment
AU2013202759A1 (en) Biomarkers and methods of treatment
HK1194974A (en) Combination treatments comprising c-met antagonists and b-raf antagonists
WO2014150819A2 (en) Biomarkers and methods of treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190910

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200407